PEG Vessel Closing Compound for Hemorrhage Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemorrhage, such as ruptured aneurysms, are often ineffective, leading to high mortality rates and lifelong disabilities, as they fail to adequately control bleeding and prevent severe consequences.
Innovation Solution
Administration of a composition containing a vessel closing compound like polyethylene glycol (PEG) with hydrophilic properties, potentially combined with magnesium salts, to diagnose and treat hemorrhaging, with specific concentration and dosage ranges for local and parenteral administration, aiming to seal blood vessels and modify blood flow.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (surgery, bed rest, medications) are used for hemorrhage, then standard care is provided, but mortality rate is high and lifelong disabilities occur
Solution Approach 1:
The patent extracts and addresses the specific problem of bleeding control separately from general hemorrhage management. By focusing on topical application of vasoconstrictors and hemostatic agents directly at the bleeding site, it isolates the bleeding control function from systemic treatments, thereby improving reliability while reducing harmful effects through targeted local action.
Solution Approach 2:
The patent applies local quality by using topical formulations with specific vasoconstrictors and hemostatic agents concentrated at the bleeding site. This local concentration provides enhanced treatment effectiveness at the specific location while avoiding systemic side effects, thereby improving reliability and reducing mortality and disability risks.
2Reliability
If a vessel closing compound is administered locally, then bleeding control is improved, but the concentration must be precisely controlled between 0.1% and 20% weight per volume
Solution Approach 1:
The patent applies parameter changes by specifying precise concentration ranges (0.1% to 20% weight per volume) for the vessel closing compound and vasoconstrictor combinations. This controlled parameter approach ensures effective bleeding control while maintaining safety margins, resolving the contradiction between reliability and manufacturing precision through defined operational parameters.
3Reliability
If a vessel closing compound is administered parenterally, then systemic effect is achieved, but the concentration must be precisely controlled between 10% and 45% weight per volume
Solution Approach 1:
The patent applies parameter changes by establishing distinct concentration ranges for different administration routes: 0.1% to 20% for local application and 10% to 45% for parenteral administration. This parameter differentiation enables reliable systemic hemorrhage control through parenteral route while maintaining precise manufacturing control through route-specific concentration guidelines.
4Reliability
If magnesium salts are added to the composition, then blood flow modification is enhanced, but the composition complexity increases
Solution Approach 1:
The patent applies merging by combining magnesium salts with vessel closing compounds and vasoconstrictors in a single topical or parenteral composition. This combination enhances blood flow control and hemorrhage management effectiveness while consolidating multiple therapeutic functions into one formulation, thereby improving reliability without excessive complexity increase.
Solution Approach 2:
The patent applies universality by creating a multi-functional composition that simultaneously provides vessel closing, vasoconstriction, and blood flow modification effects through the combination of magnesium salts with other hemostatic agents. This multi-functional approach enhances overall hemorrhage control reliability while using a single composite formulation rather than multiple separate treatments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described method effectively accumulates and retains the vessel closing compound at the hemorrhagic site, reducing bleeding area and potentially improving patient outcomes by providing a therapeutically effective dose that can be administered promptly to control hemorrhage.
Implementation Method 1
The vessel closing compound may comprise a polymer with hydrophilic properties, such as polyethylene glycol (PEG)
Data Source
AI summary
Methods of treating hemorrhage are provided, comprising diagnosing one or more hemorrhaging or potentially hemorrhaging vessels in a patient and administering to the patient a therapeutically effective amount of a composition comprising a vessel closing compound at a concentration between about 0.1% and about 45%. The vessel closing compound may comprise a polymer with hydrophilic properties, such as polyethylene glycol (PEG). The composition may also comprise one or more active agent such as a blood flow modifier with a potential to form ionic bonds with the vessel closing agent.